アプタマー市場：タイプ、用途、エンドユーザー、地域別、2026-2032年

アプタマー市場の評価、2026-2032年

アプタマーは、従来の抗体よりもサイズが小さく、安定性が高く、免疫原性が低く、製造が容易であるなど、さまざまな利点があります。これらの特性により、アプタマーは診断、治療、調査など様々な用途に有用です。市場規模は2024年に2億8,441万米ドルを超え、2032年には7億9,882万米ドルに達します。

がんや自己免疫疾患などの慢性疾患の頻度が高まるにつれ、革新的で効果的な診断・治療技術に対する需要が高まっています。アプタマーは、極めて特異的で高感度な診断やオーダーメイドの治療を開発することで、こうしたアンメット・メディカル・ニーズを満たす能力を備えています。アプタマーの選択と工学技術は進歩し、性能の向上と応用の拡大をもたらしています。コスト効率が高く効率的なアプタマーに対する需要の高まりにより、市場は2026年から2032年にかけてCAGR 15.20%で成長します。

アプタマー市場定義/概要

アプタマーは、特定の標的分子に高い親和性と特異性で結合する小さな一本鎖核酸（DNAまたはRNA）またはペプチドです。アプタマーはSELEX（Systematic Evolution of Ligands by EXponential Enrichment）と呼ばれる手順で選択され、タンパク質、低分子化合物、細胞など幅広い基質に結合できるアプタマーを同定することができます。アプタマーは抗体と似た働きをするが、サイズが小さく、合成が容易で、免疫原性が低く、安定性が高いなど、さまざまな利点があります。

アプタマーは、診断学、医薬品、バイオテクノロジーなど幅広い応用が可能です。バイオマーカーを検出するバイオセンサー、標的ドラッグデリバリーシステム、特定の疾患関連タンパク質をブロックする治療薬などに採用されています。合成生物学と生物工学が進歩するにつれて、アプタマーの潜在的な用途は、特に精密医療とテーラーメイド治療薬において拡大すると予測されます。低コストで迅速な診断ツールや集中治療を実現する能力により、アプタマーは医学研究とヘルスケアの未来にとって現実的な手段となります。

VMRの中身

業界レポートの中身

VMRのレポートには、実用的なデータと将来を見据えた分析が含まれており、ピッチの作成、ビジネスプランの作成、プレゼンテーションの構築、提案書の作成に役立ちます。

医薬品研究開発への投資増加はアプタマー市場を牽引するか？

アプタマー市場は、医薬品研究開発への投資の増加によって牽引されています。製薬会社の研究開発費は2008年の480億米ドルから2019年には830億米ドルに増加しており、革新的な治療法の発見に重点が置かれています。この投資はアプタマー研究を加速させ、標的薬送達や診断における用途を広げ、アプタマーを新規治療アプローチの不可欠な要素にしています。

アプタマー選択技術の進歩がアプタマー市場を後押ししています。SELEXのような改良された技術はアプタマーの用途を拡大し、診断や治療においてより効率的な生体分子ターゲティングを可能にしています。Journal of Medicinal Chemistryに掲載された2020年の研究によると、アプタマー特許出願は2010年から2019年の間に300%増加し、市場拡大を後押しするイノベーションの急増を示しています。

高い開発費はアプタマー市場の成長に影響を与えるか？

開発コストの高さは、アプタマーの市場開拓に影響を与える可能性があります。SELEX法のようなアプタマー開発手順は複雑で資源集約的であり、研究、技術、専門スタッフへの大規模な投資が必要となります。こうした費用は、小規模なバイオテクノロジー企業の参入を制限し、技術革新のペースを低下させる可能性があるため、アプタマーに基づく新たな治療法や診断法の導入を遅らせることになります。このような経済的障壁は、特に新興経済国や小規模研究機関において、市場の成長を阻害する可能性があります。

抗体の競合はアプタマー市場の成長に影響を与える可能性があります。抗体は長い間、診断薬や治療薬に使用されており、有効性や拡張性が実証され、バイオ医薬品ビジネスにおいて大きな存在感を示してきました。よく知られ信頼されている技術として、抗体はより多くの投資と規制当局の承認を頻繁に集めるため、アプタマーが市場の優位性を獲得するのは困難です。免疫原性の低下や製造の容易さといった利点があるにもかかわらず、アプタマーはなかなか普及しないかもしれないです。

目次

第1章 世界のアプタマー市場の導入

• 市場の導入
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 アプタマーの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 アプタマーの世界市場、タイプ別

• 概要
• RNAベース
• DNAベース
• XNAベース

第6章 アプタマーの世界市場：用途別

• 概要
• 治療薬
• 診断薬
• 調査
• 開発

第7章 アプタマーの世界市場、地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 世界のアプタマー市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第9章 企業プロファイル

• SomaLogic
• Aptamer Group
• Aptadel Therapeutics
• Base Pair Biotechnologies.
• Noxxon Pharma
• Vivonics, Inc.
• Aptagen, LLC

第10章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第10章 付録

• 関連調査

Aptamers Market Valuation - 2026-2032

Aptamers have various advantages over traditional antibodies, including smaller size, increased stability, lesser immunogenicity, and ease of manufacture. These properties make aptamers more useful for a variety of applications, including diagnostics, therapies, and research. The market size surpass USD 284.41 Million valued in 2024 to reach a valuation of around USD 798.82 Million by 2032.

The rising frequency of chronic diseases, such as cancer and autoimmune disorders, has heightened the demand for innovative and effective diagnostic and therapeutic techniques. Aptamers have the ability to meet these unmet medical needs by developing extremely specific and sensitive diagnostics and tailored treatments. Aptamer selection and engineering technologies have advanced, resulting in enhanced performance and increased applications. The rising demand for cost-effective and efficient aptamers is enabling the market grow at a CAGR of 15.20% from 2026 to 2032.

Aptamers Market: Definition/ Overview

Aptamers are small, single-stranded nucleic acids (DNA or RNA) or peptides that attach to specific target molecules with high affinity and specificity. They are chosen using a procedure known as SELEX (Systematic Evolution of Ligands by EXponential Enrichment), which allows the identification of aptamers capable of binding to a wide range of substrates, including proteins, small compounds, and even cells. Aptamers act similarly to antibodies but have various advantages, including reduced size, ease of synthesis, lesser immunogenicity, and increased stability.

Aptamers have a wide range of applications, including diagnostics, pharmaceuticals, and biotechnology. They are employed in biosensors to detect biomarkers, targeted drug delivery systems, and therapeutic medicines that block certain disease-related proteins. As synthetic biology and bioengineering improve, potential applications of aptamers are predicted to broaden, particularly in precision medicine and tailored therapeutics. Their ability to create low-cost, rapid diagnostic tools and focused treatments makes them a viable instrument for the future of medical research and healthcare.

What's inside a VMR

industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Increasing Investment in Pharmaceutical Research and Development Drive the Aptamers Market?

The market for aptamers is being driven by increased investment in pharmaceutical research and development. Pharmaceutical companies' R&D spending has increased from USD 48 Billion in 2008 to USD 83 Billion in 2019, and there is a greater emphasis on discovering innovative therapy. This investment accelerates aptamer research and broadens their uses in targeted medication delivery and diagnostics, making aptamers an essential component of novel treatment approaches.

Advances in aptamer selection technologies are propelling the aptamers market. Improved technologies, like as SELEX, are extending aptamer applications, allowing for more efficient biomolecule targeting in diagnostics and treatments. According to a 2020 study published in the Journal of Medicinal Chemistry, aptamer patent filings increased by 300% between 2010 and 2019, showing a spike in innovation that is pushing market expansion.

Will the High Development Costs Impact the Growth of the Aptamers Market?

High development costs can have an impact on the market growth for aptamers. Aptamer development procedures, like the SELEX method, are complex and resource-intensive, necessitating major investment in research, technology, and professional staff. These expenses may restrict access for smaller biotech firms and decrease the pace of innovation, thereby delaying the introduction of new aptamer-based treatments and diagnostics. This financial barrier can stifle market growth, particularly in emerging economies or small-scale research institutions.

Antibodies competition may have an impact on the growth of the aptamers market. Antibodies have long been used in diagnostics and therapies, with demonstrated efficacy, scalability, and a significant presence in the biopharmaceutical business. As a well-known and trusted technology, antibodies frequently attract more investment and regulatory approval, making it difficult for aptamers to obtain market dominance. Despite its benefits such as decreased immunogenicity and ease of manufacture, aptamers may be reluctant to gain traction.

Category-Wise Acumens

Will the Leading to a More Mature Propel the DNA-Based Segment for the Aptamers Market?

DNA-based aptamers have been the dominant segment in the aptamers market for several years. The maturation of DNA-based aptamer technology is propelling the DNA-based aptamer segment in the aptamers market. As technology advances, DNA-based aptamers provide more stability, specificity, and ease of synthesis than other types of aptamers. These developments have expanded their applications to diagnostics, treatments, and targeted medication delivery. Their rising application in biomedical research and healthcare solutions is propelling growth in this category, positioning it as a key driver in the overall aptamers market.

The increased stability of DNA aptamers over RNA aptamers is propelling the DNA-based aptamers segment of the aptamers market. DNA aptamers degrade more slowly, making them easier to handle, store, and transport. This improved stability not only lowers the costs associated with maintaining appropriate storage conditions, but it also increases their viability in a variety of applications, including diagnostics and therapies. As researchers and businesses seek dependable and long-lasting solutions, the demand for DNA-based aptamers is expected to rise, accelerating the expansion of this market.

Will the Testing and Personalized Medicine Raise the Diagnostics Segment for the for the Aptamers Market?

The diagnostics segment led the aptamers market. Testing and personalized treatment are boosting the diagnostics section of the aptamers market. The growing need for personalized healthcare solutions necessitates precise diagnostic equipment capable of identifying distinct biomarkers associated with individual patient profiles. Aptamers, with their high specificity and affinity for target molecules, are ideal for creating sensitive and accurate diagnostic tests. As personalized medicine gains pace, the demand for dependable diagnostic procedures will drive adoption of aptamer-based assays, boosting the growth of the diagnostics segment within the aptamers market.

The diagnostics segment of the aptamers market is being driven by technological improvements in the development and application of aptamers. Improvements to SELEX methodologies and test formats have increased the efficiency and accuracy of aptamer selection and application. These technological advances enable the development of highly sensitive and specific diagnostic tests for a variety of diseases, making aptamers an appealing alternative to conventional antibodies. As the demand for speedy, dependable, and cost-effective diagnostic solutions increases, the rising capabilities of aptamer technology will considerably boost the diagnostics section of the aptamers market.

Gain Access into Aptamers Market Report Methodology

Will the Strong Research Infrastructure Accelerate the North American Region for the Aptamers Market?

North America has been the dominant region in the aptamers market. North America's strong research infrastructure is driving the region's aptamer market expansion. With various academic institutions and research organizations focusing on aptamer development, the United States alone spent USD 86.4 Billion on R&D in fiscal year 2020, with a large percentage of that going toward life sciences. In Canada, the Canadian Institutes of Health Research (CIHR) financed more than CAD 1 billion in health research from 2020 to 2021, including initiatives that used aptamer technology. The National Institutes of Health (NIH) has increased financing for aptamer-related research, with a 35% increase in grants between 2015 and 2020.

The pharmaceutical industry is a primary driver of the North American aptamers market. In 2021, the U.S. biopharmaceutical sector will invest around USD 102.3 Billion in R&D, with a significant part going toward innovative treatment techniques such as aptamers. In 2018, the FDA approved a record 59 innovative drugs, several of which were biotechnology-derived. A 45% rise in businesses developing aptamer-based medicines between 2016 and 2021 demonstrates significant interest. With over 1,000 biotechnology businesses in the US and Canada researching aptamer technologies, the robust pharmaceutical ecosystem is predicted to boost the market to USD 3.9 Billion by 2028, rising at a CAGR of 17.2% over 2021.

Will the Rapid Economic Growth Expand the Asian Pacific Region for the Aptamers Market?

The Asia-Pacific region is the fastest-growing segment in the aptamers market. The aptamers market is being driven by strong economic expansion in the Asia Pacific region, as well as rising expenditure in healthcare and biotechnology. According to the Asian Development Bank, projected economic growth rates of 4.8% in 2023 and 4.9% in 2024 are driving up healthcare spending, which the WHO reports has expanded at an average annual rate of 6.6% in the Western Pacific. The biotechnology sector has experienced significant expansion. This economic momentum, together with increased R&D activity and awareness of customized medicine, puts the Asia-Pacific region as a key player in the globally aptamers market.

The government promotes the growth of the aptamers market in the Asia Pacific region by giving significant funding and strategic efforts for biotech development. For example, China's 14th Five-Year Plan prioritizes biotechnology, promising to increase R&D spending by more than 7% each year, while the National Bureau of Statistics claimed the sector had a market value of roughly USD 185 Billion in 2020, with a 15% growth projection through 2025. Japan's "Moonshot Research and Development Program" set aside roughly USD 912 Million for breakthrough technologies, including aptamers, while South Korea's expenditure of approximately USD 1.9 Billion in biotechnology R&D exemplifies this trend. India's increased financing for biotechnology research demonstrates its commitment to improving biopharmaceutical development, especially aptamer-based treatments.

Competitive Landscape

The aptamers market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the aptamers market include:

• SomaLogic
• Aptamer Group
• Aptadel Therapeutics
• Base Pair Biotechnologies
• Noxxon Pharma
• Vivonics, Inc.
• Aptagen, LLC
• TriLink Biotechnologies
• Altermune LLC
• AM Biotechnologies

Latest Developments

• In January 2023, Aptamer Group and BaseCure Therapeutics teamed to develop optimer focused therapeutics.
• In March 2022, Aptamer Sciences selected a candidate material for the "Corona-19 virus neutralizing aptamer," supporting non-clinical activities in COVID-19 treatment and vaccine development.
• In July 2021, Aptamer Sciences identified a candidate for the 'Corona 19 virus neutralizing aptamer,' progressing it as non-clinical support for COVID-19 therapy and vaccine development.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL APTAMERS MARKET

• 1.1 Introduction of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL APTAMERS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL APTAMERS MARKET, BY TYPE

• 5.1 Overview
• 5.2 RNA-Based
• 5.3 DNA-Based
• 5.4 XNA-Based

6 GLOBAL APTAMERS MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Therapeutics
• 6.3 Diagnostics
• 6.4 Research
• 6.5 Development

7 GLOBAL APTAMERS MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL APTAMERS MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 SomaLogic
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Aptamer Group
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Aptadel Therapeutics
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Base Pair Biotechnologies.
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Noxxon Pharma
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Vivonics, Inc.
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Aptagen, LLC
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

10 Appendix

• 10.1 Related Research